GeneDx Holdings Corp.
WGSHIGH VELOCITYFILING INTENSITYGeneDx Holdings Corp. reads as High Velocity (composite 70/100); pressure / disclosure signals dominate the posture this cycle · primary market Marketing & Data.
Lens
Disclosed M&A capital (2023–2025)
$45M
vs $651M in 2020–2022
Disclosed transactions
2
2/3 active fiscal years in window
Buyer archetype
Selective Buyer
Acquisition use is visible but targeted.
Composite score
70
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $696M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 36d
- 63 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 28 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 28 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 28 activism filings
- Latest activism 1.6y ago
Distress Watch
Issuers showing financial-distress filing patterns
- 28 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
- 3 non-reliance 8-Ks
- 2 auditor changes
- 1 NT late filing
- Latest event 4.2y ago; discounted
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 63 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $1.3B
- 10-Q 36d ago
- 3 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $510M · Peak count: 1
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 1 | $33M | $33M | N/A |
| 2024 | N/A | N/A | N/A | N/A |
| 2023 | 1 | $12M | $12M | N/A |
| 2022 | 1 | $141M | $141M | N/A |
| 2021 | 1 | $510M | $510M | N/A |
| 2020 | N/A | N/A | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Platform25%
- Bolt On25%
- Geographic Expansion25%
- Technology Acquisition25%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- platform
- bolt_on
- geographic_expansion
- technology_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“Consistent with our acquisition strategy, we have identified the following criteria to evaluate prospective target businesses. We intend to seek to acquire companies in the Life Sciences Tools, Synthetic Biology and Diagnostics fields and that we believe:”
“Centrellis® integrates digital tools and artificial intelligence, allowing our scientists to ingest and synthesize clinical and genomic data to deliver better, more comprehensive health insights.”
“GeneDx was acquired by and integrated with Sema4 Holdings, adding Legacy Sema4’s Centrellis®, a highly innovative health information platform to our portfolio of solutions.”
“we continue to use the proceeds from our July 2021 business combination and related private placement financing to accelerate growth”
“we intend to apply capital over time to make targeted acquisitions to accelerate our ability to reach a wider range of patients”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Marketing & Data
- Market spend (2023–2025)
- $51.4B
- Market spend (2020–2022)
- $63.5B
- Recent vs prior
- −19%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
Trading comparables unavailable for this wedge.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)72026-02-23
- 10-Q (quarterly)172026-05-04
- 8-K (event)632026-05-04
- Proxy / DEF 14A272026-04-30
- Activism (13D / DFAN / PREC)282024-11-20
Signals on file
- critical
Non-reliance disclosure
2022-03-143 Item 4.02 filings on file; financial-statement non-reliance.
- elevated
Auditor change
2021-08-162 Item 4.01 filings on file; certifying accountant change.
- watch
Late-filing notice
2021-05-181 NT 10-K/10-Q filing on file.
- elevated
Activism on file
2024-11-2028 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Restatement risk
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.